George P Studzinski
Overview
Explore the profile of George P Studzinski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kalia V, Studzinski G, Sarkar S
J Leukoc Biol
. 2021 Jan;
110(4):809-819.
PMID: 33464639
Vitamin D, a key nutrient/prohormone classically associated with skeletal health, is also an important immunomodulator, with pleotropic effects on innate and adaptive immune cells. Outcomes of several chronic, autoimmune, and...
2.
Wang X, Gupta P, Jramne Y, Danilenko M, Liu D, Studzinski G
Oncotarget
. 2020 Sep;
11(33):3129-3143.
PMID: 32913557
Hepatocellular carcinoma (HCC) has increasing worldwide incidence but when unresectable lacks curative options. Treatment with a kinase inhibitor Sorafenib (Sf), while initially effective, results in only short increases in patient...
3.
Wu Q, Wang X, Pham K, Luna A, Studzinski G, Liu C
J Steroid Biochem Mol Biol
. 2019 Nov;
197:105524.
PMID: 31704246
Hepatocellular carcinoma (HCC) is the most common form of liver cancer and it is the third leading cause of global cancer mortality. Sorafenib (Sf) is the first oral multi-kinase inhibitor...
4.
Wang X, Dawod A, Nachliely M, Harrison J, Danilenko M, Studzinski G
J Cell Physiol
. 2019 Jun;
235(1):573-586.
PMID: 31245853
Acute myeloid leukemia (AML) has a poor prognosis and requires new approaches for treatment. We have reported that a combination of vitamin D-based cell differentiation agents (doxercalciferol/carnosic acid [D2/CA]) added...
5.
Wang X, Beute W, Harrison J, Studzinski G
J Steroid Biochem Mol Biol
. 2017 Aug;
177:149-154.
PMID: 28765039
Numerous clinical studies of vitamin D, its derivatives or analogs, have failed to clearly demonstrate sustained benefits when used for the treatment of human malignant diseases. However, given the strong...
6.
Zheng R, Studzinski G
J Cell Biochem
. 2016 Dec;
118(6):1583-1589.
PMID: 27922189
Cytarabine (AraC) has been the primary treatment agent for acute myeloid leukemia (AML) in the past 30 years, but the precise mechanism of its action is not completely known. Here...
7.
Zheng R, Studzinski G
Leuk Lymphoma
. 2016 Oct;
58(6):1468-1480.
PMID: 27748139
Differentiation therapy can supplement the therapy of APL, but other subtypes of AML are treated principally with cytotoxic agents, with few lasting remissions. While the induction of monocyte followed by...
8.
Wang X, Harrison J, Studzinski G
J Steroid Biochem Mol Biol
. 2016 Sep;
173:139-147.
PMID: 27637326
Vitamin D has so far not fulfilled its early promise as an antineoplastic agent, in spite of compelling in vitro data. With the aim of bringing vitamin D or its...
9.
Harrison J, Wang X, Studzinski G
Oncotarget
. 2016 May;
7(24):36447-36460.
PMID: 27144333
Acute Myeloid Leukemia (AML) has grave prognosis due to aggressive nature of the disease, the toxicity of standard treatment, and overall low cure rates. We recently showed that AML cells...
10.
Gocek E, Studzinski G
J Cell Biochem
. 2016 Apr;
117(8):1733-44.
PMID: 27122067
The role of vitamin D as a treatment option for neoplastic diseases, once considered to have a bright future, remains controversial. The preclinical studies discussed herein show compelling evidence that...